A live attenuated strain of Yersinia pestis KIM as a vaccine against plague.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Vaccine

• Publication date

  2011-04-05

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.vaccine.2011.01.099PMID 21320544PMCID PMC3073832
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Yersinia pestis with Regulated Delayed Attenuation as a Vaccine Candidate To Induce Protective Immunity against Plague

  2010cited by this paper
• D27-pLpxL, an Avirulent Strain of Yersinia pestis, Primes T Cells That Protect against Pneumonic Plague

  2009cited by this paper
• Pleiotropic effects of the lpxM mutation in Yersinia pestis resulting in modification of the biosynthesis of major immunoreactive antigens.

  2009cited by this paper
• The Role of relA and spoT in Yersinia pestis KIM5+ Pathogenicity

  2009cited by this paper
• Absence of Inflammation and Pneumonia during Infection with Nonpigmented Yersinia pestis Reveals a New Role for the pgm Locus in Pathogenesis

  2009cited by this paper
• Purification and mutagenesis of LpxL, the lauroyltransferase of Escherichia coli lipid A biosynthesis.

  2008cited by this paper
• Braun Lipoprotein (Lpp) Contributes to Virulence of Yersiniae: Potential Role of Lpp in Inducing Bubonic and Pneumonic Plague

  2008cited by this paper
• Salmonella enterica Serovar Typhimurium Strains with Regulated Delayed Attenuation In Vivo

  2008cited by this paper
• Highly Efficient Method for Introducing Successive Multiple Scarless Gene Deletions and Markerless Gene Insertions into the Yersinia pestis Chromosome

  2008cited by this paper
• Current challenges in the development of vaccines for pneumonic plague

  2008cited by this paper
• Immune defense against pneumonic plague

  2008cited by this paper
• Characterization of a mouse model of plague after aerosolization of Yersinia pestis CO92.

  2008cited by this paper
• Yersinia pestis Evades TLR4-dependent Induction of IL-12(p40)2 by Dendritic Cells and Subsequent Cell Migration1

  2008cited by this paper
• Immunogenicity of the rF1+rV vaccine for plague with identification of potential immune correlates.

  2007cited by this paper
• RovA, a global regulator of Yersinia pestis, specifically required for bubonic plague

  2006cited by this paper
• Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response

  2006influential reference
• Molecular and physiological insights into plague transmission, virulence and etiology.

  2006cited by this paper
• Progression of primary pneumonic plague: a mouse model of infection, pathology, and bacterial transcriptional activity.

  2005cited by this paper
• From the recent lessons of the Malagasy foci towards a global understanding of the factors involved in plague reemergence.

  2005cited by this paper
• A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague

  2004cited by this paper
• Yersinia pestis (plague) vaccines

  2004cited by this paper
• Protection against plague afforded by immunisation with DNA vaccines optimised for expression of the Yersinia pestis V antigen.

  2004cited by this paper
• Synergistic Protection of Mice against Plague with Monoclonal Antibodies Specific for the F1 and V Antigens of Yersinia pestis

  2003cited by this paper
• Yersinia pestis and the plague.

  2003cited by this paper
• Interleukin-10 and Inhibition of Innate Immunity to Yersiniae: Roles of Yops and LcrV (V Antigen)

  2003cited by this paper
• Genome Sequence of Yersinia pestis KIM

  2002cited by this paper
• Botulinum toxin as a biological weapon: medical and public health management.

  2001cited by this paper
• Characterization of the Yersinia pestisYfu ABC Inorganic Iron Transport System

  2001cited by this paper
• Yersinia pestis and plague.

  2001cited by this paper
• Transferable plasmid-mediated resistance to streptomycin in a clinical isolate of Yersinia pestis.

  2001cited by this paper
• Vaccination against bubonic and pneumonic plague.

  2001cited by this paper
• Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.

  2000cited by this paper
• One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products.

  2000cited by this paper
• Effect of cold shock on lipid A biosynthesis in Escherichia coli. Induction At 12 degrees C of an acyltransferase specific for palmitoleoyl-acyl carrier protein.

  1999cited by this paper
• Plague manual--epidemiology, distribution, surveillance and control.

  1999cited by this paper
• Yersiniosis I: Microbiological and Clinicoepidemiological Aspects of Plague and Non-Plague Yersinia Infections

  1999cited by this paper
• The SCID/Beige mouse as a model to investigate protection against Yersinia pestis.

  1999cited by this paper
• Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.

  1999cited by this paper
• Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine.

  1998cited by this paper
• Yersinia pestis--etiologic agent of plague

  1997cited by this paper
• Recent emergence of new variants of Yersinia pestis in Madagascar

  1997cited by this paper
• Resistance to lipopolysaccharide mediated by the Yersinia pestis V antigen-polyhistidine fusion peptide: amplification of interleukin-10

  1997cited by this paper
• ISOLATION AND IDENTIFICATION OF YERSINIA PESTIS RESPONSIBLE FOR THE RECENTPLAGUE OUTBREAKS IN INDIA

  1996cited by this paper
• Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis

  1996cited by this paper
• A comparison of Plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model.

  1995cited by this paper
• Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague

  1995cited by this paper
• A new improved sub-unit vaccine for plague: the basis of protection.

  1995cited by this paper
• Update: human plague--India, 1994.

  1994cited by this paper
• Distribution of 3-hydroxy iC17:0 in subgingival plaque and gingival tissue samples: relationship to adult periodontitis

  1994cited by this paper
• Construction of an ASD+ Expression-Cloning Vector: Stable Maintenance and High Level Expression of Cloned Genes in a Salmonella Vaccine Strain

  1988cited by this paper
• Virulence genes regulated at the transcriptional level by Ca2+ in Yersinia pestis include structural genes for outer membrane proteins

  1986influential reference
• In vivo comparison of avirulent Vwa- and Pgm- or Pstr phenotypes of yersiniae

  1984cited by this paper
• Roles of V antigen in promoting virulence and immunity in yersiniae.

  1984cited by this paper
• The Vwa+ virulence factor of yersiniae: the molecular basis of the attendant nutritional requirement for Ca++.

  1983cited by this paper
• Live, attenuated Yersinia pestis vaccine: virulent in nonhuman primates, harmless to guinea pigs.

  1974cited by this paper
• Plague immunization. I. Past and present trends.

  1974cited by this paper
• Pathogenicity and Immunogenic Efficacy of a Live Attenuated Plague Vaccine in Vervet Monkeys

  1973cited by this paper
• Effectiveness of live or killed plague vaccines in man.

  1970cited by this paper
• [IMMUNITY IN PLAGUE. ACQUISITIONS SUPPLIED BY 30 YEARS OF WORK ON THE "PASTEURELLA PESTIS EV" (GIRARD AND ROBIC) STRAIN].

  1963cited by this paper
• STUDIES ON LYSOGENESIS I

  1951cited by this paper
• A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS

  1938cited by this paper

• Virulence Reduction in Yersinia pestis by Combining Delayed Attenuation with Plasmid Curing

  2025cites this paper
• Bacterial Vaccines with Regulated Delayed Attenuation

  2024cites this paper
• Lung Resident Memory T Cells Activated by Oral Vaccination Afford Comprehensive Protection against Pneumonic Yersinia pestis Infection.

  2022cites this paper
• Lipid A Variants Activate Human TLR4 and the Noncanonical Inflammasome Differently and Require the Core Oligosaccharide for Inflammasome Activation

  2022cites this paper
• Remodeling Yersinia pseudotuberculosis to generate a highly immunogenic outer membrane vesicle vaccine against pneumonic plague

  2022cites this paper
• Human TLR4 and noncanonical inflammasome differ in their ability to respond to distinct lipid A variants

  2021cites this paper
• Protection Elicited by Attenuated Live Yersinia pestis Vaccine Strains against Lethal Infection with Virulent Y. pestis

  2021cites this paper
• Protection and Safety Evaluation of Live Constructions Derived from the Pgm− and pPCP1− Yersinia pestis Strain

  2020cites this paper
• Mucosal Approaches for Systemic Immunity to Anthrax, Brucellosis, and Plague

  2020cites this paper
• Induction of Protective Antiplague Immune Responses by Self-Adjuvanting Bionanoparticles Derived from Engineered Yersinia pestis

  2020cites this paper
• Современное состояние проблемы разработки вакцин для специфической профилактики чумы

  2019cites this paper
• Molecular alterations induced by Yersinia pestis, dengue virus and Staphylococcal enterotoxin B under severe stress.

  2019cites this paper
• A Dopamine-Responsive Signal Transduction Controls Transcription of Salmonella enterica Serovar Typhimurium Virulence Genes

  2019cites this paper
• Chapter 12 Plague vaccines: status and future

  2019cites this paper
• Current State of the Problem of Vaccine Development for Specific Prophylaxis of Plague

  2019cites this paper
• Plague vaccine: recent progress and prospects

  2019cites this paper
• A Recombinant Attenuated Yersinia pseudotuberculosis Vaccine Delivering a Y. pestis YopENt138-LcrV Fusion Elicits Broad Protection against Plague and Yersiniosis in Mice

  2019cites this paper
• Plague Vaccines: Status and Future.

  2016cites this paper
• Genome and Evolution of Yersinia pestis.

  2016cites this paper
• Biosynthetically engineered lipopolysaccharide as vaccine adjuvant

  2015cites this paper
• Oral administration of a recombinant attenuated Yersinia pseudotuberculosis strain elicits protective immunity against plague.

  2015cites this paper
• Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: An update for 2011-2012.

  2015cites this paper
• Rational considerations about development of live attenuated Yersinia pestis vaccines.

  2014cites this paper
• Pushing the Bacterial Envelope

  2014cites this paper
• LcrV Delivered via Type III Secretion System of Live Attenuated Yersinia pseudotuberculosis Enhances Immunogenicity against Pneumonic Plague

  2014cites this paper
• The delicate balance in genetically engineering live vaccines.

  2014cites this paper
• Rational Considerations about Development of Live Attenuated Y. pestis Vaccines

  2014cites this paper
• Pathogenicity of Yersinia pestis Synthesis of 1-Dephosphorylated Lipid A

  2013cites this paper
• Live-attenuated Yersinia pestis vaccines

  2013cites this paper
• Christian Raetz: scientist and friend extraordinaire.

  2013cites this paper
• Crp Induces Switching of the CsrB and CsrC RNAs in Yersinia pseudotuberculosis and Links Nutritional Status to Virulence

  2012cites this paper
• Amino acid substitutions in LcrV at putative sites of interaction with Toll-like receptor 2 do not affect the virulence of Yersinia pestis.

  2012cites this paper
• Lipopolysaccharide of Yersinia pestis, the Cause of Plague: Structure, Genetics, Biological Properties

  2012cites this paper
• Omics strategies for revealing Yersinia pestis virulence

  2012cites this paper
• Deletion of the Braun Lipoprotein-Encoding Gene and Altering the Function of Lipopolysaccharide Attenuate the Plague Bacterium

  2012cites this paper
• Advances in Development of Countermeasures for Potential Biothreat Agents

  2012cites this paper
• Recent Advancement in the Development of Vaccines Against Y. pestis - A Potential Agent of Bioterrorism

  2012cites this paper
• Its Immunogenicity Exhibits Low Endotoxic Activity while Retaining 1-Monophosphorylated Lipopolysaccharide Correction: Salmonella Synthesizing

  2012cites this paper
• Progress on plague vaccine development

  2011cites this paper
• Retaining Its Immunogenicity Exhibits Low Endotoxic Activity while 1-Monophosphorylated Lipopolysaccharide Synthesizing Salmonella

  2011cites this paper
• Correction: Salmonella Synthesizing 1-Monophosphorylated Lipopolysaccharide Exhibits Low Endotoxic Activity while Retaining Its Immunogenicity

  2011cites this paper
• Developing live vaccines against plague.

  2011cites this paper
• Enhanced humoral and mucosal immune responses after intranasal immunization with chimeric multiple antigen peptide of LcrV antigen epitopes of Yersinia pestis coupled to palmitate in mice.

  2011cites this paper
• Salmonella Synthesizing 1-Monophosphorylated Lipopolysaccharide Exhibits Low Endotoxic Activity while Retaining Its Immunogenicity

  2011cites this paper
• Developing live vaccines against Yersinia pestis

  2011cites this paper
• The Role of Immune Correlates and Surrogate Markers in the Development of Vaccines and Immunotherapies for Plague

  2011cites this paper
• Plague: Infections of Companion Animals and Opportunities for Intervention.

  2011cites this paper